Megafunding rounds and regulatory momentum reshaped the biotech investment landscape, signaling growing confidence in transformative clinical innovation.
Megafunding rounds and regulatory momentum reshaped the biotech investment landscape, signaling growing confidence in transformative clinical innovation.
In a shareholder letter released on 1 April 2025, MAIA Biotechnology revealed plans to advance telomere‐targeted therapies in …
The sudden departure of FDA’s Peter Marks raises uncertainty across the biopharma sector amid ongoing regulatory scrutiny and …
The European regulatory body’s February 2025 meeting brings fresh treatment options for immunodeficiency and autoimmunity among other conditions, …
February 2025 sees a surge in large-scale biotech investments—from Eikon’s massive Series D to critical autoimmune and oncology …
Innovation, investment, and ideals intersected dramatically at the AI Action Summit—held 10–11 February at Paris’s Grand Palais. Co-chaired …
The 26th Clinical Trial Supply Europe conference (25–26 February, Barcelona) will showcase how AI, logistics innovation, and regulatory …
Novartis confirmed its acquisition of Anthos Therapeutics for up to $3.1 billion—securing a promising Phase III-stage anticoagulant aimed at …
On February 1, 2025, the U.S. Food and Drug Administration (FDA) approved Eli Lilly’s lebrikizumab, marking the first …
January’s investment activity saw a wave of biotech Series funding, with Verdiva Bio, Aviceda Therapeutics, Windward Bio, and …
Already a subscriber? Log in